Delivery Order SPE2DB22D3301-SPE2DB25FY8LC
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension in 60 ml quantities, valued at $1,182.78. This firm fixed-price delivery order, with an ultimate completion date of July 22, 2025, represents a non-competitive set-aside award and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The contract is issued as a child order under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension in a 180 ml quantity. This is a firm fixed-price delivery order with a ceiling value of $3,763.02 and an ultimate completion date of July 28, 2025. The contract was competitively awarded without set-aside restrictions and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a delivery order valued at $2,957.94 to AmerisourceBergen Drug Corp for Quillivant XR 25 mg/5 mL suspension (120 mL) on July 22, 2025, with completion scheduled for July 23, 2025. This firm fixed price delivery order was issued on a non-set-aside basis and represents a pediatric ADHD medication supply under AmerisourceBergen's existing contract vehicle with DLA. The product will be delivered to the company's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Quillivant XR 25 mg/5 mL suspension in a 180 mL quantity, with a ceiling value of $1,307.94. This is a firm fixed-price delivery order issued without set-aside designation, indicating competitive award. The contract is scheduled for ultimate completion on July 29, 2025, with performance taking place at AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a $3,274.31 delivery order to AmerisourceBergen Drug Corp for Quillivant XR 25 mg/5 ml suspension (60 ml), a pharmaceutical product used in treating attention deficit hyperactivity disorder. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The delivery order...
- The Defense Logistics Agency awarded a delivery order valued at $1,202.16 to AmerisourceBergen Drug Corp for Quillivant XR 25 mg/5 mL suspension (150 mL), a medication used to treat attention deficit hyperactivity disorder. The award was made on July 21, 2025, with a completion date of July 22, 2025, under a firm fixed-price delivery order contract with no set-aside designation. The product will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is...
- The Defense Logistics Agency awarded a $1,108.41 delivery order to AmerisourceBergen Drug Corp for Quillivant XR 25 mg/5 ml suspension (120 ml) on July 25, 2025, with an ultimate completion date of July 28, 2025. This firm fixed-price contract utilizes no set-aside designation and is being performed at the awardee's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a pediatric ADHD medication procurement supporting military and federal healthcare systems....
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension in a 150 ml quantity, with a ceiling value of $1,383.36. This is a firm fixed price delivery order with no set-aside designation, issued competitively as part of AmerisourceBergen's broader pharmaceutical supply relationship with the federal government. The contract is scheduled for completion by July 23, 2025, with performance at the...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,974.70 firm fixed-price contract is for the supply of Quillivant XR 25 mg/5 ml suspension, a medication used to treat attention-deficit/hyperactivity disorder (ADHD). The contract is not set-aside and has an ultimate completion date of May 1, 2025. AmerisourceBergen Drug Corp holds a larger $999,999,999.00 Indefinite...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,327.20 firm fixed-price contract is for the supply of Quillivant XR 25 mg/5 ml suspension, a medication used to treat attention-deficit/hyperactivity disorder (ADHD). The contract has an ultimate completion date of November 24, 2023 and was awarded on November 22, 2023. This delivery order is part...
- SPE2DB22D3301Indefinite Delivery Contract
- SPE2DB22D3301-SPE2DB25FY8LCDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $2,625.30 to AmerisourceBergen Drug Corp for the supply of Quillivant XR 25 mg/5 mL suspension in 120 mL quantities, with an ultimate completion date of July 29, 2025. This non-set-aside, firm fixed-price contract was competitively awarded on July 28, 2025, with performance to be executed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a transaction under the company's broader pharmaceutical supply relationship with the federal government. This delivery order operates as a child contract under AmerisourceBergen Drug Corp's Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a comprehensive global pharmaceutical support vehicle valued at $999,999,999.00 and extending through December 2026. The IDC enables the company to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs worldwide. Quillivant XR, an attention-deficit/hyperactivity disorder medication, falls within the neurological treatment category that AmerisourceBergen routinely provides to support Defense Health Agency and other federal healthcare systems through this flexible contract vehicle.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.6k | 7/28/25 |